君实生物(01877.HK) 发盈警,预计2024年度净亏损约12.92亿人民币(下同),较上年度减少9.91亿元,减幅43.42%。归因商业化药品的销售收入增加,带动营业收入增长,年内,营业收入预计增长29.7%至19.49亿元;研发费用减少34.2%至12.74亿元。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-17 16:25。)
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/10/29 | 第三季业绩 | 无派息 |
2024/08/30 | 中期业绩 | 无派息 |
2024/04/29 | 第一季业绩 | 无派息 |
2024/03/28 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.